Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Twincore Centre for Experimental and Clinical Infection Research, Hannover, Germany.
Nat Commun. 2022 Sep 5;13(1):5215. doi: 10.1038/s41467-022-32906-9.
Hemochromatosis is one of the most common inherited metabolic diseases among white populations and predominantly originates from a homozygous C282Y mutation in the HFE gene. The G > A transition at position c.845 of the gene causes misfolding of the HFE protein, ultimately resulting in its absence at the cell membrane. Consequently, the lack of interaction with the transferrin receptors 1 and 2 leads to systemic iron overload. We screened potential gRNAs in a highly precise cell culture assay and applied an AAV8 split-vector expressing the adenine base editor ABE7.10 and our candidate gRNA in 129-Hfe mice. Here we show that a single injection of our therapeutic vector leads to a gene correction rate of >10% and improved iron metabolism in the liver. Our study presents a proof-of-concept for a targeted gene correction therapy for one of the most frequent hereditary diseases affecting humans.
血色病是白人中最常见的遗传性代谢疾病之一,主要源于 HFE 基因中 C282Y 突变的纯合子。该基因 c.845 位的 G > A 转换导致 HFE 蛋白错误折叠,最终导致其在细胞膜上缺失。因此,缺乏与转铁蛋白受体 1 和 2 的相互作用导致全身铁过载。我们在高度精确的细胞培养测定中筛选了潜在的 gRNA,并在 129-Hfe 小鼠中应用了表达腺嘌呤碱基编辑器 ABE7.10 的 AAV8 分裂载体和我们的候选 gRNA。在这里,我们表明单次注射我们的治疗载体可导致基因校正率 >10%,并改善肝脏中的铁代谢。我们的研究为针对影响人类的最常见遗传性疾病之一的靶向基因校正治疗提供了概念验证。